1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate

A research team from Italy recently published a report in the Central European Journal of Urology on two patients undergoing transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® (registered trademark of ProstaLund AB) before a holmium laser enucleation of the prostate (HoLEP)1. The patients also received moderate sedation/analgesia during the procedure.

General or spinal anaesthesia are the most common anaesthetic modalities used during HoLEP, depending on the surgeon's and anaesthesiologist's preference, patient characteristics, comorbidity, and patient choice. However, general anaesthesia can impact postoperative recovery and expose patients to anaesthesia-related complications. To further reduce the invasiveness of HoLEP, the research team evaluate the feasibility, safety, and advantages of the use of TUIA via the Schelin Catheter®.

The authors conclude that preliminary results demonstrate that TUIA via the Schelin Catheter® was safe and feasible, providing effective operative and postoperative pain control while shortening hospitalization and treatment time.

Reference:
1. Romagnoli D et al. Holmium laser enucleation of the prostate with transurethral intraprostatic anaesthesia using Schelin catheter: a preliminary communication. Cent European J Urol. 2024;77: 273-277.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About Schelin Catheter®

The Schelin Catheter® is a transurethral catheter with a retractable needle enabling sterile intraprostatic injections of pharmaceuticals during diagnostic or treatment procedures for the prostate. The Schelin Catheter® is primarily used for transurethral intraprostatic anaesthesia (TUIA) during minimal invasive treatments for benign prostatic enlargement offering effective pain control, replacing the need for general or spinal anaesthesia. For more information visit, www.schelincatheter.com.

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement (BPE). The company has patented the CoreTherm® Concept, a customised thermal treatment for BPE. ProstaLund is listed on Nasdaq First North Growth Market and has approximately 3,600 shareholders. For more information, visit www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate

Datum 2024-10-04, kl 13:00
Källa MFN
Bifogade filer
First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!